Concordance (Cohen’s κ) between BASDAI 50, CPDAI < 4, DAPSA ≤ 3.3, PR, and MDA at months 4, 8, and 12 after the start of anti-TNF therapy.
| Measures | T4 | T8 | T12 |
|---|---|---|---|
| DAPSA vs MDA | 0.57 | 0.29 | 0.63 |
| DAPSA vs PR | 0.39 | 0.40 | 0.18 |
| DAPSA vs CPDAI | 0.47 | 0.37 | 0.43 |
| DAPSA vs BASDAI 50 | 0.29 | 0.19 | 0.15 |
| MDA vs PR | 0.47 | 0.20 | 0.30 |
| MDA vs CPDAI | 0.70 | 0.54 | 0.54 |
| MDA vs BASDAI 50 | 0.57 | 0.31 | 0.28 |
| PR vs CPDAI | 0.51 | 0.28 | 0.20 |
| PR vs BASDAI 50 | 0.38 | 0.46 | 0.52 |
| CPDAI vs BASDAI 50 | 0.62 | 0.46 | 0.30 |
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; CPDAI: Composite Psoriatic Disease Activity Index; DAPSA: Disease Activity Index for Psoriatic Arthritis; PR: partial remission; MDA: minimal disease activity; TNF: tumor necrosis factor.